What is Leerink Partnrs’ Estimate for Geron FY2024 Earnings?

Geron Co. (NASDAQ:GERN) – Investment analysts at Leerink Partnrs decreased their FY2024 earnings estimates for Geron in a report issued on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now forecasts that the biopharmaceutical company will post earnings of ($0.29) per share for the year, down from their previous estimate of ($0.28). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q4 2024 earnings at ($0.06) EPS, Q1 2025 earnings at ($0.03) EPS, FY2025 earnings at $0.00 EPS and FY2026 earnings at $0.19 EPS.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The business had revenue of $28.27 million during the quarter, compared to analyst estimates of $18.97 million. During the same quarter in the previous year, the business earned ($0.08) earnings per share. The company’s revenue for the quarter was up 17138.4% compared to the same quarter last year.

GERN has been the topic of several other reports. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Geron in a research note on Tuesday, December 10th. Barclays raised shares of Geron to a “strong-buy” rating in a research note on Friday, November 29th. Scotiabank initiated coverage on shares of Geron in a research note on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Geron in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $7.15.

Geron Stock Up 0.6 %

Shares of NASDAQ GERN opened at $3.42 on Wednesday. The firm has a market capitalization of $2.07 billion, a price-to-earnings ratio of -10.69 and a beta of 0.55. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89. Geron has a 52-week low of $1.64 and a 52-week high of $5.34. The stock has a 50 day moving average price of $3.83 and a 200 day moving average price of $4.24.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in GERN. Exome Asset Management LLC purchased a new position in shares of Geron in the 3rd quarter valued at about $4,109,000. Alternative Investment Advisors LLC. increased its position in shares of Geron by 13.3% in the third quarter. Alternative Investment Advisors LLC. now owns 22,209 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 2,612 shares in the last quarter. Franklin Resources Inc. boosted its position in shares of Geron by 461.4% in the 3rd quarter. Franklin Resources Inc. now owns 79,923 shares of the biopharmaceutical company’s stock worth $331,000 after buying an additional 65,687 shares in the last quarter. World Investment Advisors LLC grew its stake in Geron by 10,151.4% in the 3rd quarter. World Investment Advisors LLC now owns 1,029,553 shares of the biopharmaceutical company’s stock valued at $4,674,000 after acquiring an additional 1,019,510 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Geron by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 13,067,999 shares of the biopharmaceutical company’s stock valued at $59,339,000 after acquiring an additional 231,178 shares in the last quarter. 73.71% of the stock is owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.